Prolonged Edoxaban in Patients With Low Body Weight and Cancer-Associated Isolated Distal Deep Vein Thrombosis.

ABSTRACT:

Background

The ONCO DVT study revealed that 12-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (IDDVT) was superior to 3-month edoxaban treatment. However, the influence of body weight on efficacy and safety remains unknown.

Objectives

We compared 12-month and 3-month edoxaban treatments in patients with low body weight and cancer-associated IDDVT.

Methods

In this prespecified subgroup analysis of the ONCO DVT study, we divided patients by body weight with a 60 kg cutoff. The primary endpoint was symptomatic recurrent venous thromboembolism or venous thromboembolism-related death at 12 months.

Results

Of the 601 participants, 426 had low body weight, 99% receiving a reduced dose of edoxaban. The 1-year primary endpoint rate w

SUBMITTER: Nagai T 

PROVIDER: S-EPMC12271068 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature